Mark Germain Acquires 120 Million Shares of SCNI
Mark Germain significantly increases his stake in SCNI with a major share purchase.
Key Points
- On June 16, 2026, Mark Germain purchased 120 million shares of SCNI, boosting his stake significantly.
- SCNI shares traded at $0.32, with other institutional investors adjusting their positions.
- CEO Amir Reichman also bought 400 million shares, indicating notable insider activity.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Mark Germain made a notable move by purchasing 120 million shares of SCNI on June 16, 2026. This acquisition reflects a significant increase in his investment in the company. The transaction was not part of a pre-arranged trading plan.
Other Institutional Activity in SCNI
While Germain was increasing his position, several institutional investors were adjusting theirs. XTX Topco Ltd reduced its holdings by 3,253 shares, ending with 24,041 shares valued at approximately $13,283. UBS Group AG also cut its stake by 829 shares, leaving it with 919 shares worth about $524. Meanwhile, Northwestern Mutual Wealth Management Co and Citadel Advisors LLC exited their positions entirely, shedding 1,000 and 34,562 shares, respectively.
Scinai Immunotherapeutics Ltd. Stock Down 87.1%
Shares of SCNI traded at around $0.32. The stock's recent trading activity shows a fluctuation in investor interest, with both insider and institutional transactions taking place.
Insider Buying and Selling at Scinai Immunotherapeutics Ltd.
In addition to Mark Germain's purchase, SCNI's Chief Executive Officer, Amir Reichman, acquired 400 million shares on the same day. This insider buying activity signals confidence in the company's prospects.
Bottom Line
Mark Germain's acquisition of 120 million SCNI shares is a significant development in the company's insider activity. It highlights a strong vote of confidence in SCNI from its insiders. Investors often watch such transactions closely as they can indicate management's view on the company's future potential.
Get Scinai Immunotherapeutics Ltd. alerts
New 13F filings, insider trades, and analyst moves on $SCNI, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.